Corporate Governance - Twist Bioscience held its 2026 annual meeting of stockholders via an online webcast, focusing on electing directors, conducting a non-binding advisory vote on executive compensation, and ratifying the independent auditor for fiscal 2026 [2] - All three director nominees—Keith Crandell, Jan Johannessen, and Trynka Shineman Blake—were elected, and the advisory vote on executive compensation was approved [6] Meeting Logistics - The meeting was chaired by Lead Independent Director Robert Chess, with attendance from various directors and company officers, including CEO Emily Leproust [3][4] - The board set December 26, 2025, as the record date for determining stockholders entitled to vote, with proxies received for 56,260,506 shares, representing approximately 91.81% of total votes [5][6] Auditor Ratification - Stockholders ratified Ernst & Young LLP as the auditor for fiscal 2026, with a full vote tally to be filed on Form 8-K within four business days [6]

Core Viewpoint - The pharmaceutical industry is experiencing growth due to persistent human demand and unmet needs, alongside increased R&D investments by companies, marking the transition to an "innovation-driven" revenue era in China [1]. Group 1: Index Performance - The CSI Hong Kong Stock Connect Pharmaceutical and Health Comprehensive Index rose by 2.1% [1]. - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 2.0% [1]. - The CSI Biotechnology Theme Index saw a rise of 0.6% [1]. - The CSI Innovative Drug Industry Index grew by 0.4% [1]. - The CSI 300 Pharmaceutical and Health Index experienced a slight increase of 0.2% [1]. Group 2: Index Composition - The index focuses on leading innovative drug companies in A-shares, comprising no more than 50 stocks involved in innovative drug R&D [5]. - The index tracks leading biotechnology companies in A-shares, including no more than 50 stocks related to gene diagnostics, biopharmaceuticals, and other human biotechnology [7]. - The index covers leading companies in the pharmaceutical and health industry within the CSI 300, including segments like chemical pharmaceuticals, medical services, and medical devices [9]. Group 3: Valuation Metrics - The rolling P/E ratio for the innovative drug index is 50.4 times, with a valuation increase of 72.3% since its inception [6]. - The rolling P/E ratio for the biotechnology index is 53.2 times, with a valuation increase of 58.7% since its inception [8]. - The rolling P/E ratio for the CSI 300 Pharmaceutical and Health Index is 29.9 times, with a valuation increase of 39.2% since its inception [10].

智通财经APP讯，中生北控生物科技(08247)公布，由于杨鹏先生、高光侠博士、沈胜博士、沈佐君教授 及何欣博士的董事任期已于股东特别大会上届满且彼等均因希望投入更多时间在其他事务而不愿意接受 重新委任，(a)杨鹏先生、高光侠博士、沈胜博士均不再担任非执行董事;(b) 沈佐君教授不再担任独立非 执行董事、薪酬委员会主席、审核委员会及提名委员会各自的成员;及(c)何欣博士不再担任独立非执行 董事、审核委员会、提名委员会及薪酬委员会各自的成员，均自2026年2月9日起生效。 相关委任获股东于股东特别大会上批准后，康睿女士已获委任为非执行董事及金腾川教授已获委任为独 立非执行董事，执行董事兼总裁陈鹏先生已获委任为主席，陈正永先生不再担任主席，惟仍将担任执行 董事;均自2026年2月9日起生效。 ...

Core Viewpoint - The market is experiencing a shift from a "style betting" approach to a "structural competition" approach, indicating a more nuanced investment landscape where various asset classes coexist simultaneously [6][26]. Group 1: Market Dynamics - Since the beginning of 2026, the market has shown significant volatility with rapid shifts in sentiment, leading to a perception of a lack of clear direction [1]. - Observing ETF-level capital flows reveals that the market is accommodating multiple directions rather than lacking direction [2]. - A notable change is occurring in the aesthetic of capital, suggesting a stratification in investment preferences [3][4]. Group 2: Technology Sector Insights - The A+H technology sector is emerging as a focal point in the current structural layering of the market [8]. - Historically, technology assets were viewed as temporary trading tools rather than structural assets, with narratives shifting between growth potential and risk concerns [9][10]. - As of 2025, the understanding of technology is evolving to focus on its role within the industrial structure rather than just valuation [12][13]. Group 3: Hong Kong Stock Market Developments - The narrative surrounding Hong Kong technology stocks is shifting from "repair" to "technological transformation," reflecting a more balanced understanding of their role in the global market [14][15]. - The Guozhen Hong Kong Stock Connect Technology Index emphasizes a balanced approach, focusing on companies with stable growth and R&D investment across various sectors [16][19]. Group 4: Artificial Intelligence and Future Trends - The market's perception of artificial intelligence is evolving from a conceptual level to a more structured understanding of its industry chain positioning [20]. - The Zhongzheng Innovation and Entrepreneurship AI Index represents a comprehensive view of the AI industry, covering various layers from infrastructure to applications [23][24]. Group 5: Stability and Structural Evolution - The market is forming a multi-layered structure where technology assets represent high growth potential, while stable cash flow assets serve as stabilizers [25]. - The Zhongzheng Hong Kong Stock Connect High Dividend Select Index introduces a quality screening mechanism, focusing on companies with strong dividend attributes and structural integrity [25]. - The overall trend indicates a shift towards a more structured investment approach, reflecting the maturation of capital and the integration of the Chinese capital market into the global system [26][27].

经济观察网2026年2月9日，深交所官网披露了格林生物科技股份有限公司首次公开发行股票招股说明书 (申报稿)，公司IPO材料被正式受理。根据招股书，格林生物科技股份有限公司拟于深圳证券交易所创 业板上市，保荐机构为长江证券承销保荐有限公司，本次公开发行股票数量不超过3,333.33万股，占发 行后总股本的比例不低于25%。 ...

天眼查App显示，涉事企业山阴县佳鹏生物科技有限公司成立于去年6月，法定代表人为宁建伟，注册 资本500万人民币，经营范围包括生物饲料研发、煤炭及制品销售、建筑材料销售等，由张佳鹏全资持 股。变更记录显示，去年8月，该公司曾两度变更法定代表人。 据媒体报道，2月9日，国务院安委办对山西朔州佳鹏生物科技有限公司"2.7"较大爆炸事故查处挂牌督 办。据悉，该爆炸事故已造成8人遇难。 ...

会议要求，用心用情做好冬春救助和受灾群众温暖过冬工作， 督促地方尽快将中央冬春救助资金发放到位 ，对受灾群众的居住、取暖等情况进行再排 查，发现问题快速核实、及时解决。要会同相关部门滚动做好春节期间灾害风险会商研判，指导督促高风险地区强化应急准备，预置救援力量和物资，确 保出现突发情况及时高效应对处置。 2月9日，应急管理部召开会议，对春节前后事故灾害防范应对工作进行再部署再落实。 会议强调，近期重大涉险和较大事故多发，必须拿出切实管用的硬措施，严密防控重点领域安全风险。 要督促春节假期不停工的矿山、危化品、工贸等高危企业技术和管理人员在岗履责，对动火作业、检维修等严格审批。推动有关部门继续强化燃 气、渔业船舶、特种设备等领域风险隐患排查整治。 要提高政治站位、增强敏锐性，深刻吸取近期事故教训，举一反三抓隐患排查整治，切实把防的工作做足做实做到位，坚决防范遏制重特大事故。 要提升及时发现问题、及时排除风险的能力，综合运用人防、物防、技防等措施，对安全生产违法违规行为早发现、早处置，切实把事故隐患消灭 在萌芽状态。 要围绕春节、春运安全，推动相关部门加强道路交通、铁路民航、客运码头等交通运输安全监管，做好热门景 ...

来源：市场资讯 通过天眼查大数据分析，无锡合佑生生物科技有限公司共对外投资了1家企业。 天眼查信息显示，无锡合佑生生物科技有限公司的股东为：周斌、上海源清流生物科技合伙企业（有限 合伙）、上海创生之源生物科技合伙企业（有限合伙）、余茂倩。 2月9日，天眼查融资历程显示，无锡合佑生生物科技有限公司近日获得"Pre-A轮"融资，涉及融资金额 数千万人民币，投资机构为金投致源。 资料显示，无锡合佑生生物科技有限公司法定代表人为周斌，成立于2025年，位于无锡市，是一家以从 事研究和试验发展为主的企业。企业注册资本1000万人民币，并已于2026年完成了Pre-A轮，交易金额 数千万人民币。 ...

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors needing to consider the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry will rely more on key data releases, actual transactions, and visibility on earnings realization or turning points [1] Group 2: Sector Insights - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing potential, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Junshi Biosciences, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector is maintained with a neutral outlook, indicating that while the industry has bottomed out, recovery will take time [1] - Recommended stocks include Angelalign Technology and Weigao Group [1]

Core Viewpoint - The strong trend in the mainland healthcare sector from last year is expected to continue into this year, with investors considering the value of more R&D pipelines when evaluating valuations [1] Group 1: Investment Strategy - Companies are now trading based more on actual execution capabilities rather than solely on licensing deal expectations [1] - Achieving returns that exceed the industry average this year will rely more on key data releases, actual transactions, and visibility on profit realization or turning points [1] Group 2: Sector Analysis - The outlook for CDMO companies is becoming more constructive due to accelerated growth, strong product cycles, limited geopolitical risks, and reasonable valuations [1] - The ratings for WuXi AppTec and WuXi AppTec Holdings have been upgraded to "Buy" [1] Group 3: Selective Strategy in Biotech and Pharma - A selective strategy is adopted for biotech and pharmaceutical companies, favoring those with key data releases and early data showing some promise, along with actual transaction expectations [1] - Companies such as Kelun-Biotech, Innovent Biologics, and Hansoh Pharmaceutical are viewed positively [1] Group 4: Medical Devices Sector - The medical devices sector maintains a neutral outlook, as the industry has bottomed out but requires time for gradual recovery [1] - Recommendations include buying Angelalign Technology and Weigao Group [1]